Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

IMPORTANCE: A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence. OBJECTIVES: To evaluate the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sims, Matthew D., Khanna, Sahil, Feuerstadt, Paul, Louie, Thomas J., Kelly, Colleen R., Huang, Edward S., Hohmann, Elizabeth L., Wang, Elaine E. L., Oneto, Caterina, Cohen, Stuart H., Berenson, Charles S., Korman, Louis, Lee, Christine, Lashner, Bret, Kraft, Colleen S., Ramesh, Mayur, Silverman, Michael, Pardi, Darrell S., De, Ananya, Memisoglu, Asli, Lombardi, David A., Hasson, Brooke R., McGovern, Barbara H., von Moltke, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926325/
https://www.ncbi.nlm.nih.gov/pubmed/36780159
http://dx.doi.org/10.1001/jamanetworkopen.2022.55758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926325/
https://www.ncbi.nlm.nih.gov/pubmed/36780159
http://dx.doi.org/10.1001/jamanetworkopen.2022.55758

Ejemplares similares